Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Pancreatic Cancer Metastatic × Paclitaxel × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 113 Carcinoma, Non-Small-Cell Lung 108 Ovarian Neoplasms 67 Fallopian Tube Neoplasms 39 Lung Neoplasms 32 Carcinoma, Ovarian Epithelial 28 Parkinson Disease 4, Autosomal Dominant Lewy Body 24 Endometrial Neoplasms 23 Uterine Cervical Neoplasms 22 Triple Negative Breast Neoplasms 19 Neoplasms 19 Esophageal Neoplasms 19 Neoplasm Metastasis 16 Stomach Neoplasms 15 Esophageal Squamous Cell Carcinoma 14 Carcinoma 11 Recurrence 10 Brenner Tumor 10 Urinary Bladder Neoplasms 8 Squamous Cell Carcinoma of Head and Neck 8 Head and Neck Neoplasms 8 Adenocarcinoma of Lung 8 Peritoneal Neoplasms 6 Adenocarcinoma 5 Inflammatory Breast Neoplasms 4 Carcinoma, Squamous Cell 4 Adenocarcinoma Of Esophagus 4 Urethral Neoplasms 3 Thoracic Neoplasms 3 Respiratory Tract Neoplasms 3

Interventions

folfirinox 1 devimistat 1 Paclitaxel 1 Oxaliplatin 1 Leucovorin 1 Irinotecan 1 Injections 1 Gemcitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06752811 2026-02-10

pompom

Shanghai Yizhong Pharmaceutical Co., Ltd.

Phase 3 Recruiting

Gastrointestinal

Pancreatic Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡